<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="171398">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865124</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-000564</org_study_id>
    <secondary_id>1R01HL087060-01A2</secondary_id>
    <nct_id>NCT00865124</nct_id>
  </id_info>
  <brief_title>Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease</brief_title>
  <official_title>Role of Mineralocorticoid Receptor in Diabetic Cardiovascular Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aldosterone is a significant mediator of cardiovascular injury associated with heart failure
      and the cardiovascular benefits of mineralocorticoid receptor blockade are additive to those
      of angiotensin converting enzyme inhibitors or angiotensin II receptor blockers. This study
      will test the hypothesis that MR antagonists exert beneficial cardiovascular effects,
      specifically by decreasing vascular injury and improving vascular function.A randomized,
      double-blind study will be conducted, in which subjects with Type 2 Diabetes Mellitus will
      undergo a series of assessments to test heart, blood vessel, and kidney function at
      baseline, and after 2 and 6 months of treatment with one of the following drugs:

        1. spironolactone

        2. hydrochlorothiazide plus potassium

        3. placebo.

      In the event of insufficient funds, randomization to the placebo arm will be stopped and
      primary assessment of outcomes will occur at baseline and after 6 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MR blockade improves coronary circulatory and cardiac diastolic function in individuals with T2DM</measure>
    <time_frame>two and six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>MR blockade improves renovascular function in subjects with T2DM</measure>
    <time_frame>two and six months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Vascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MR blockade (Spironolactone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hydrochlorothiazide + potassium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
    <description>25 mg daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydrochlorothiazide + potassium</intervention_name>
    <description>12.5 mg hydrochlorothiazide daily plus 10mEq potassium</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-70 years

          -  type 2 diabetes mellitus

          -  with or without hypertension

        Exclusion Criteria:

          -  ischemic changes on resting electrocardiogram,

          -  clinical evidence of heart disease (angina, heart failure, unstable
             angina),cerebrovascular or peripheral vascular disease,

          -  significant cardiac arrhythmias,

          -  aortic stenosis,

          -  2nd or 3rd degree atrio-ventricular block, sinus node disease, or symptomatic
             bradycardia,

          -  bronchospastic lung disease with active wheezing,

          -  known hypersensitivity to adenosine,

          -  hemoglobin A1C &gt; 8.5%, *

          -  gout (If not already taking HCTZ),

          -  the use of Rosiglitazone,**

          -  eGFR &lt; 60 ml/min,

          -  serum potassium &gt; 5.0 mmol/L,

          -  use of potassium-sparing diuretics,**

          -  current smoker,*

          -  pregnancy,

          -  renal disease not related to diabetes mellitus,

          -  uncontrolled hypertension, systolic BP &gt;160 mm Hg and diastolic BP &gt;100 mm Hg,*

          -  use of cyclic hormone replacement therapy

          -  past intolerance of ACE inhibitor therapy

          -  other major medical illnesses. Subjects with evidence of a previous myocardial
             infarction on the first adenosine-stimulated PET study will be withdrawn from the
             study.

          -  Screening systolic blood pressure &lt; 105 mm Hg off of anti-hypertensive medications

               -  Subjects can enroll in study and proceed with in-patient evaluations if during
                  the run-in period adjustments of medications, diet and habits lead to improved
                  glucose control (equivalent to HbA1c &lt;8.5%), controlled hypertension and
                  cessation of smoking.

                    -  Subjects who are currently taking these medications will not qualify for a
                       screening visit. If medications were recently stopped by the subject's
                       physician, he or she may be screened but the baseline assessment protocol
                       must occur 3 months after stopping.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gail K Adler, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 31, 2013</lastchanged_date>
  <firstreceived_date>March 17, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Gail Kurr Adler</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Mineralocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
